HU192112B - Process for preparing new 4-oxo-4h-/1/-benzo-pyran-8-yl-alkanecarboxylic acids - Google Patents
Process for preparing new 4-oxo-4h-/1/-benzo-pyran-8-yl-alkanecarboxylic acids Download PDFInfo
- Publication number
- HU192112B HU192112B HU823764A HU376482A HU192112B HU 192112 B HU192112 B HU 192112B HU 823764 A HU823764 A HU 823764A HU 376482 A HU376482 A HU 376482A HU 192112 B HU192112 B HU 192112B
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- alkyl
- oxo
- benzopyran
- phenyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 17
- 150000007513 acids Chemical class 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 33
- -1 alkali metal cyanide Chemical class 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 238000010992 reflux Methods 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- ZPSZTJUSHMIKRF-UHFFFAOYSA-N 8-(bromomethyl)chromen-4-one Chemical compound BrCC1=CC=CC=2C(C=COC=21)=O ZPSZTJUSHMIKRF-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 claims 1
- 229910000831 Steel Inorganic materials 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims 1
- 239000004312 hexamethylene tetramine Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000000047 product Substances 0.000 description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
- 238000005481 NMR spectroscopy Methods 0.000 description 33
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 239000002244 precipitate Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- TZZNWMJZDWYJAZ-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 TZZNWMJZDWYJAZ-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- NICASFMXSIRBMU-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)acetonitrile Chemical compound O1C2=C(CC#N)C=CC=C2C(=O)C=C1C1=CC=CC=C1 NICASFMXSIRBMU-UHFFFAOYSA-N 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WOHGZBOYXIVEIT-UHFFFAOYSA-N 2-(2-cyclohexyl-4-oxochromen-8-yl)acetonitrile Chemical compound O1C2=C(CC#N)C=CC=C2C(=O)C=C1C1CCCCC1 WOHGZBOYXIVEIT-UHFFFAOYSA-N 0.000 description 2
- UPCQUKIGLJNPJG-UHFFFAOYSA-N 2-(2-methyl-4-oxochromen-8-yl)acetonitrile Chemical compound C1=CC(CC#N)=C2OC(C)=CC(=O)C2=C1 UPCQUKIGLJNPJG-UHFFFAOYSA-N 0.000 description 2
- OMJAGKNZNQYHRT-UHFFFAOYSA-N 2-(4-oxo-2,3-diphenylchromen-8-yl)acetonitrile Chemical compound C=1C=CC=CC=1C=1OC2=C(CC#N)C=CC=C2C(=O)C=1C1=CC=CC=C1 OMJAGKNZNQYHRT-UHFFFAOYSA-N 0.000 description 2
- BWYAJVAESQFWLH-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BWYAJVAESQFWLH-UHFFFAOYSA-N 0.000 description 2
- DUSGKPRWSSXDNR-UHFFFAOYSA-N 2-(4h-chromen-8-yl)acetic acid Chemical compound C1C=COC2=C1C=CC=C2CC(=O)O DUSGKPRWSSXDNR-UHFFFAOYSA-N 0.000 description 2
- UZDADURTZCCYBX-UHFFFAOYSA-N 2-(6-methoxy-4-oxo-2-phenylchromen-8-yl)acetonitrile Chemical compound C=1C(=O)C2=CC(OC)=CC(CC#N)=C2OC=1C1=CC=CC=C1 UZDADURTZCCYBX-UHFFFAOYSA-N 0.000 description 2
- PXDPYVSPUBJYGI-UHFFFAOYSA-N 2-(6-methyl-4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound C=1C(=O)C2=CC(C)=CC(CC(O)=O)=C2OC=1C1=CC=CC=C1 PXDPYVSPUBJYGI-UHFFFAOYSA-N 0.000 description 2
- JTWZDLKLIFKAMV-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)-4-oxochromen-8-yl]acetonitrile Chemical compound COC1=CC=CC(C=2OC3=C(CC#N)C=CC=C3C(=O)C=2)=C1 JTWZDLKLIFKAMV-UHFFFAOYSA-N 0.000 description 2
- BSMWETPLQKJEMF-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)-4-oxochromen-8-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=CC=CC(CC(O)=O)=C2O1 BSMWETPLQKJEMF-UHFFFAOYSA-N 0.000 description 2
- OHWXSQNTEHKJCC-UHFFFAOYSA-N 2-[2-(4-methylphenyl)-4-oxochromen-8-yl]acetonitrile Chemical compound C1=CC(C)=CC=C1C1=CC(=O)C2=CC=CC(CC#N)=C2O1 OHWXSQNTEHKJCC-UHFFFAOYSA-N 0.000 description 2
- KQBPGEJCBQDTAM-UHFFFAOYSA-N 2-[2-(furan-2-yl)-4-oxochromen-8-yl]acetonitrile Chemical compound O1C2=C(CC#N)C=CC=C2C(=O)C=C1C1=CC=CO1 KQBPGEJCBQDTAM-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- VFNAAUOSXUBYFV-UHFFFAOYSA-N 8-(bromomethyl)-2-phenylchromen-4-one Chemical compound BrCC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 VFNAAUOSXUBYFV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000490229 Eucephalus Species 0.000 description 2
- 241001079660 Phanes Species 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 1
- SQDDGOVNJMIFFT-UHFFFAOYSA-N 1,1-bis(diethoxyphosphoryl)-n,n-dimethylmethanamine Chemical compound CCOP(=O)(OCC)C(N(C)C)P(=O)(OCC)OCC SQDDGOVNJMIFFT-UHFFFAOYSA-N 0.000 description 1
- VGVJLJSWNHDQNR-UHFFFAOYSA-N 2-(2-benzyl-4-oxochromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2CC1=CC=CC=C1 VGVJLJSWNHDQNR-UHFFFAOYSA-N 0.000 description 1
- XFOCAHDAJXWNBA-UHFFFAOYSA-N 2-(2-benzyl-4-oxochromen-8-yl)acetonitrile Chemical compound O1C2=C(CC#N)C=CC=C2C(=O)C=C1CC1=CC=CC=C1 XFOCAHDAJXWNBA-UHFFFAOYSA-N 0.000 description 1
- IWRSUCYIHRYMGX-UHFFFAOYSA-N 2-(2-cyclohexyl-4-oxochromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1CCCCC1 IWRSUCYIHRYMGX-UHFFFAOYSA-N 0.000 description 1
- CJPZVNVWVHMBRW-UHFFFAOYSA-N 2-(2-methyl-4-oxochromen-8-yl)acetic acid Chemical compound C1=CC(CC(O)=O)=C2OC(C)=CC(=O)C2=C1 CJPZVNVWVHMBRW-UHFFFAOYSA-N 0.000 description 1
- QTEYJXQDEBFAGS-UHFFFAOYSA-N 2-(2-naphthalen-2-yl-4-oxochromen-8-yl)acetic acid Chemical compound C1=CC=CC2=CC(C=3OC4=C(C(C=3)=O)C=CC=C4CC(=O)O)=CC=C21 QTEYJXQDEBFAGS-UHFFFAOYSA-N 0.000 description 1
- XSQMCAKZTBULOS-UHFFFAOYSA-N 2-(2-naphthalen-2-yl-4-oxochromen-8-yl)acetonitrile Chemical compound C1=CC=CC2=CC(C3=CC(C4=CC=CC(CC#N)=C4O3)=O)=CC=C21 XSQMCAKZTBULOS-UHFFFAOYSA-N 0.000 description 1
- BWJOQFQALICWAJ-UHFFFAOYSA-N 2-(4-oxo-2,3-diphenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2C=3C=CC=CC=3)=O)=C1OC=2C1=CC=CC=C1 BWJOQFQALICWAJ-UHFFFAOYSA-N 0.000 description 1
- FMQFDPXKSNAJLI-UHFFFAOYSA-N 2-(4-oxo-3-phenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C2=O)=C1OC=C2C1=CC=CC=C1 FMQFDPXKSNAJLI-UHFFFAOYSA-N 0.000 description 1
- MMKPKJLHQJYKFA-UHFFFAOYSA-N 2-(6-methoxy-4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound C=1C(=O)C2=CC(OC)=CC(CC(O)=O)=C2OC=1C1=CC=CC=C1 MMKPKJLHQJYKFA-UHFFFAOYSA-N 0.000 description 1
- SJIHSGHFVQYTGU-UHFFFAOYSA-N 2-(6-methyl-4-oxo-2-phenylchromen-8-yl)acetonitrile Chemical compound C=1C(=O)C2=CC(C)=CC(CC#N)=C2OC=1C1=CC=CC=C1 SJIHSGHFVQYTGU-UHFFFAOYSA-N 0.000 description 1
- FOIBLIYJQWFQHK-UHFFFAOYSA-N 2-(6-methyl-4-oxo-2-phenylchromen-8-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC(C)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 FOIBLIYJQWFQHK-UHFFFAOYSA-N 0.000 description 1
- SFIYTPVSHXBPKV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(6-methyl-4-oxo-2-phenylchromen-8-yl)acetate Chemical compound CCN(CC)CCOC(=O)CC1=CC(C)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 SFIYTPVSHXBPKV-UHFFFAOYSA-N 0.000 description 1
- DLARMASZNXPTIV-UHFFFAOYSA-N 2-(diethylamino)ethyl 3-(4-oxo-2-phenylchromen-8-yl)prop-2-enoate Chemical compound CCN(CC)CCOC(=O)C=CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 DLARMASZNXPTIV-UHFFFAOYSA-N 0.000 description 1
- BIHNWLPVWKTLBK-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-4-oxochromen-8-yl]acetonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=CC=CC(CC#N)=C2O1 BIHNWLPVWKTLBK-UHFFFAOYSA-N 0.000 description 1
- MHSHHTISTHKEHD-UHFFFAOYSA-N 2-[2-(4-methylphenyl)-4-oxochromen-8-yl]acetic acid Chemical compound C1=CC(C)=CC=C1C1=CC(=O)C2=CC=CC(CC(O)=O)=C2O1 MHSHHTISTHKEHD-UHFFFAOYSA-N 0.000 description 1
- KQATUEDHHVEQDM-UHFFFAOYSA-N 2-[2-(furan-2-yl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CO1 KQATUEDHHVEQDM-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KHSJXDWFRGYVSF-UHFFFAOYSA-N 3,5-dimethyl-2-phenylchromen-4-one Chemical compound CC=1C(=O)C=2C(C)=CC=CC=2OC=1C1=CC=CC=C1 KHSJXDWFRGYVSF-UHFFFAOYSA-N 0.000 description 1
- OMMUAHSIJPMKRS-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-8-yl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 OMMUAHSIJPMKRS-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- KTHHDZVGZNVCOE-UHFFFAOYSA-N 4-oxo-3-phenylchromene-8-carbaldehyde Chemical compound O=CC1=CC=CC(C2=O)=C1OC=C2C1=CC=CC=C1 KTHHDZVGZNVCOE-UHFFFAOYSA-N 0.000 description 1
- KUHLPDFFVKSOLQ-UHFFFAOYSA-N 8-hydroxy-3-methyl-2-phenylchromen-4-one Chemical compound O1C2=C(O)C=CC=C2C(=O)C(C)=C1C1=CC=CC=C1 KUHLPDFFVKSOLQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100021999 Cytosolic Fe-S cluster assembly factor NUBP2 Human genes 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101001107795 Homo sapiens Cytosolic Fe-S cluster assembly factor NUBP2 Proteins 0.000 description 1
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000377350 Puan Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8122020A FR2516922A1 (fr) | 1981-11-25 | 1981-11-25 | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU192112B true HU192112B (en) | 1987-05-28 |
Family
ID=9264332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU823764A HU192112B (en) | 1981-11-25 | 1982-11-23 | Process for preparing new 4-oxo-4h-/1/-benzo-pyran-8-yl-alkanecarboxylic acids |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US4602034A (enExample) |
| EP (1) | EP0080934B1 (enExample) |
| JP (1) | JPS5896082A (enExample) |
| AT (1) | ATE31927T1 (enExample) |
| AU (1) | AU563190B2 (enExample) |
| CA (1) | CA1213595A (enExample) |
| CS (1) | CS248035B2 (enExample) |
| DD (1) | DD204919A5 (enExample) |
| DE (1) | DE3277970D1 (enExample) |
| DK (1) | DK164163C (enExample) |
| ES (1) | ES8308323A1 (enExample) |
| FR (1) | FR2516922A1 (enExample) |
| HU (1) | HU192112B (enExample) |
| IE (1) | IE54130B1 (enExample) |
| IL (1) | IL67291A0 (enExample) |
| IN (1) | IN158843B (enExample) |
| MA (1) | MA19650A1 (enExample) |
| MX (1) | MX173498B (enExample) |
| NO (1) | NO159169C (enExample) |
| NZ (1) | NZ202596A (enExample) |
| OA (1) | OA07257A (enExample) |
| SU (1) | SU1250171A3 (enExample) |
| YU (2) | YU43726B (enExample) |
| ZA (1) | ZA828436B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2536397A2 (en) * | 1981-11-25 | 1984-05-25 | Lipha | [4-oxo-4H-1-Benzopyran-8-yl]alkanoic acids, their salts and derivatives, their preparation and medicinal products containing them |
| DE3311004A1 (de) * | 1983-03-25 | 1984-09-27 | Bayer Ag, 5090 Leverkusen | Chromon- und thiochromon-8-aldehyde, sowie ein verfahren zu ihrer herstellung |
| JPS62215581A (ja) * | 1986-03-18 | 1987-09-22 | Koichi Shiyudo | フラボンカルボン酸誘導体 |
| IL85554A0 (en) * | 1987-03-02 | 1988-08-31 | Takeda Chemical Industries Ltd | Chromone derivatives |
| IL89840A (en) * | 1988-04-06 | 1996-10-31 | Lipha | Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them |
| US5116954A (en) * | 1988-04-06 | 1992-05-26 | Lipha, Lyonnaise Industrielle Pharmaceutique | Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety |
| USH1427H (en) * | 1988-04-06 | 1995-04-04 | Briet; Phillipe | Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2 |
| US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| KR910700240A (ko) * | 1989-01-19 | 1991-03-14 | 로버트 애이. 아미테이지 | 플루오르화된 플라본 아세트산 |
| US5238954A (en) * | 1989-01-19 | 1993-08-24 | The Upjohn Company | Fluorinated flavone acetic acid |
| PL173781B1 (pl) * | 1992-02-05 | 1998-04-30 | Boehringer Ingelheim Kg | Sposób wytwarzania nowych pochodnych amidyny |
| US5703130A (en) * | 1995-06-07 | 1997-12-30 | Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences | Chalcone retinoids and methods of use of same |
| US5716982A (en) * | 1995-06-07 | 1998-02-10 | Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences | Retinoids and methods of use of same |
| US5968940A (en) * | 1995-06-08 | 1999-10-19 | Institute Of Materia Medica | Retinoids and methods of use of same |
| JP4638098B2 (ja) * | 1999-06-14 | 2011-02-23 | キャンサー・リサーチ・テクノロジー・リミテッド | 癌治療 |
| WO2001052839A1 (en) | 2000-01-24 | 2001-07-26 | Mruk Jozef S | Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes |
| EP1311262A4 (en) * | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | CANCER THERAPY THROUGH COMBINATION THERAPY |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| BRPI0614965A2 (pt) * | 2005-08-26 | 2016-09-13 | Antisoma Plc | método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit |
| EP2470174A1 (en) | 2009-08-27 | 2012-07-04 | Merck Patent GmbH | Use of faa and its derivatives in cosmetics and dermatology |
| LT2496567T (lt) * | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| CN103304531A (zh) * | 2013-06-25 | 2013-09-18 | 南方医科大学 | 一种3-芳基黄酮乙酸 |
| US20200115358A1 (en) * | 2016-03-11 | 2020-04-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Icariin and icaritin derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2921070A (en) * | 1957-11-05 | 1960-01-12 | Recordati Lab Farmacologico S | Basic esters of 3-methylflavone-8-carboxylic acid |
| US3350411A (en) * | 1963-10-10 | 1967-10-31 | Pharma Seceph S A Soc D Expl C | Process for preparing 3-methylflavone-8-carboxylic acid |
| BE757821A (fr) * | 1970-08-01 | 1971-04-01 | Recordati Chem Pharm | Procede de preparation de l'acide 3-propionyl-salicylique et dederives de cet acide |
| GB1479518A (en) * | 1973-12-27 | 1977-07-13 | Erba Carlo Spa | 5,6-benzo-ypsilon-pyrone derivatives |
| US4148900A (en) * | 1973-12-27 | 1979-04-10 | Carlo Erba S.P.A. | 5:6-Benzo-γ-pyrone derivatives and process for their preparation |
| FR2281112A1 (fr) * | 1974-08-05 | 1976-03-05 | Lipha | Nouveau medicament choleretique et anti-inflammatoire |
| GB1469823A (en) * | 1974-08-13 | 1977-04-06 | Farma Lepori | Flavone derivatives |
| DE2549745A1 (de) * | 1974-11-20 | 1976-05-26 | Lipha | Durch einen chromonylrest substituierte propionsaeuren sowie deren derivate und verwendungen |
-
1981
- 1981-11-25 FR FR8122020A patent/FR2516922A1/fr active Granted
-
1982
- 1982-11-16 ZA ZA828436A patent/ZA828436B/xx unknown
- 1982-11-17 IL IL67291A patent/IL67291A0/xx not_active IP Right Cessation
- 1982-11-18 IN IN848/DEL/82A patent/IN158843B/en unknown
- 1982-11-18 IE IE2752/82A patent/IE54130B1/en not_active IP Right Cessation
- 1982-11-19 AU AU90730/82A patent/AU563190B2/en not_active Ceased
- 1982-11-23 HU HU823764A patent/HU192112B/hu not_active IP Right Cessation
- 1982-11-24 MA MA19863A patent/MA19650A1/fr unknown
- 1982-11-24 NZ NZ202596A patent/NZ202596A/en unknown
- 1982-11-24 DK DK523082A patent/DK164163C/da not_active IP Right Cessation
- 1982-11-24 SU SU823516803A patent/SU1250171A3/ru active
- 1982-11-24 DE DE8282402137T patent/DE3277970D1/de not_active Expired
- 1982-11-24 AT AT82402137T patent/ATE31927T1/de not_active IP Right Cessation
- 1982-11-24 ES ES517637A patent/ES8308323A1/es not_active Expired
- 1982-11-24 EP EP82402137A patent/EP0080934B1/fr not_active Expired
- 1982-11-24 MX MX010425A patent/MX173498B/es unknown
- 1982-11-24 NO NO823940A patent/NO159169C/no unknown
- 1982-11-24 CS CS828426A patent/CS248035B2/cs unknown
- 1982-11-25 JP JP57205582A patent/JPS5896082A/ja active Granted
- 1982-11-25 CA CA000416354A patent/CA1213595A/fr not_active Expired
- 1982-11-25 OA OA57850A patent/OA07257A/xx unknown
- 1982-11-25 YU YU2649/82A patent/YU43726B/xx unknown
- 1982-11-25 DD DD82245217A patent/DD204919A5/de unknown
-
1984
- 1984-09-21 YU YU1630/84A patent/YU43675B/xx unknown
- 1984-11-06 US US06/669,037 patent/US4602034A/en not_active Expired - Fee Related
-
1986
- 1986-05-29 US US06/872,381 patent/US4783533A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3476883B2 (ja) | ヘテロ環含有カルボン酸誘導体 | |
| SU1424732A3 (ru) | Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей | |
| SU1250171A3 (ru) | Способ получени производных @ 4-(4н)-оксо-8-бензопиранил @ -уксусной кислоты | |
| US3420851A (en) | Novel dibenzoxepines | |
| EP0783496B9 (en) | Thiazolidinedione derivatives, their production and use | |
| US6335353B1 (en) | Orally active iron (III) chelators | |
| CA1041504A (en) | Amino derivatives of pyrazolopyridine carboxamides | |
| EP2496230B1 (en) | Ire-1 alpha inhibitors | |
| EP0220573B1 (de) | Heterocyclische Verbindungen | |
| DE69405624T2 (de) | Pharmazeutische Verbindungen | |
| HU200761B (en) | Process for producing chromone derivatives and pharmaceutical compositions comprising same as active ingredient | |
| US4539326A (en) | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents | |
| EP0259972B1 (en) | Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals | |
| US3833594A (en) | Amino derivatives of pyrazolopyridine carboxylic acids and esters | |
| US3590041A (en) | Novel halo-substituted cinnamic acid heterocyclic amides | |
| CN102020640A (zh) | 四氢吲哚酮和四氢吲唑酮衍生物、其制备方法及其在医药上的应用 | |
| IL28432A (en) | New fantasy histories of the tetracycline type and processes for their preparation | |
| US5736558A (en) | 4-(6-fluoro-1,2-benzisoxazolyl)-1 piperidinyl-propoxy-chromen-4-one-one-derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety | |
| SU893133A3 (ru) | Способ получени производных 1-/3-(3,4,5-триметоксифенокси)-2-пропил/-4-арилпиперазина | |
| EP0368464B1 (en) | Thiopene-2 carboxamide derivatives and their pharmaceutical use | |
| HU177341B (en) | Process for producing new substituted hexahydro-benzopirano-square bracket-3,2-c-square bracket closed-pyridines | |
| RU2207340C2 (ru) | Способ получения 1,2,3,9-тетрагидро-9-метил-3-[(2-метил-1н-имидазол-1-ил)метил]-4н-карбазол -4-она или его фармацевтически приемлемых солей | |
| US6448273B1 (en) | Orally active iron (III) chelators | |
| JPH0641113A (ja) | オキシム誘導体、その製造方法並びに該化合物を含有するロイコトリエン媒介疾患及び医学的症状で使用するための製薬学的組成物 | |
| Muškinja et al. | CYTOTOXIC POTENTIAL OF NOVEL N-FORMYL PYRAZOLINES DERIVED FROM VANILLIN. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |